Abstract C184: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate

Conclusions: BIND-510 exhibits differentiated PK, tumor accumulation, tolerability and anti-tumor activity compared to VCR. In combination with the demonstration of PSMA expression in hematological cancers, our findings support the feasibility of developing BIND-510 as a targeted clinical therapy with the potential benefit of reduced toxicity and improved anti-tumor activity compared to currently available treatments in hematological as well as solid tumor settings.Citation Format: Louise Cadzow, Kristen Arnold, Daniel Thrasher, James Nolan, Allen Horhota, Eric Lewis-Clark, James Wright, Susan Low. BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C184.

Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Cadzow, L., Arnold, K., Thrasher, D., Nolan, J., Horhota, A., Lewis-Clark, E., Wright, J., Low, S. Tags: Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts Source Type: research